Select Page
FAQs -website size

Frequently Asked Questions 


When is Bortezomib (Velcade) treatment used? 



Bortezomib, a type of cancer treatment drug,  it is a plasma-cell-depleting proteasome inhibitor.

Proteasomes are in cells. They help to break down proteins that the cell doesn’t need. Bortezomib blocks the proteasomes so the proteins build up inside the cell. The cell then dies.  Cell death is called apoptosis (cell suicide).

When a patient with a severe case of autoimmune encephalitis,  is resistant to responding to treatment,  this is called ‘refractory’ to the treatment, the doctor may consider using Bortezomib. Bortezomib is considered when the patient is refractory to Rituxan/Rituximab a standard immunosuppressive and B-cell-depleting drug. 

Studies have shown Bortezomib as a promising escalation treatment that has had clinical improvement or disease remission is such cases, and with noted success in anti-NMDAr encephalitis. 


Our website is not a substitute for independent professional medical advice. Nothing contained on our website is intended to be used as medical advice. No content is intended to be used to diagnose, treat, cure or prevent any disease, nor should it be used for therapeutic purposes or as a substitute for your own health professional's advice. Although THE INTERNATIONAL AUTOIMMUNE ENCEPHALITIS SOCIETY  provides a great deal of information about AUTOIMMUNE ENCEPHALITIS, all content is provided for informational purposes only. The International Autoimmune Encephalitis Society  cannot provide medical advice.

International Autoimmune Encephalitis Society is a charitable non-profit 501(c)(3) organization founded in 2016 by Tabitha Andrews Orth, Gene Desotell and Anji Hogan-Fesler. Tax ID# 81-3752344. Donations raised directly supports research, patients, families and caregivers impacted by autoimmune encephalitis and to educating healthcare communities around the world. Financial statement will be made available upon request.

Translate »